RT Book, Section A1 Blaha, Michael J. A2 Papadakis, Maxine A. A2 McPhee, Stephen J. A2 Rabow, Michael W. A2 McQuaid, Kenneth R. SR Print(0) ID 1193133379 T1 Overview: Lipid Disorders T2 Current Medical Diagnosis & Treatment 2023 YR 2023 FD 2023 PB McGraw-Hill Education PP New York, NY SN 9781264687343 LK accessmedicine.mhmedical.com/content.aspx?aid=1193133379 RD 2024/10/06 AB The “Lipid Hypothesis” of CVD—stating that cholesterol is causal in the development of atherosclerotic CVD (ASCVD) and that lowering cholesterol is associated with lower cardiovascular event rates—is widely accepted throughout the medical community. For patients with known CVD (secondary prevention), studies have shown that cholesterol lowering leads to a consistent reduction in total mortality and in recurrent cardiovascular events in men and women; other studies have documented lowered mortality and events in middle-aged and older patients. Among patients without CVD (primary prevention), the data are generally consistent, with rates of cardiovascular events, heart disease mortality, and all-cause mortality differing among studies. Treatment guidelines have been designed to assist clinicians in selecting patients for cholesterol-lowering therapy based predominantly on their overall risk of developing CVD as well as their baseline cholesterol levels.